Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Joanna M. Day
Observed names:
Day, J.M.,
Day, Joanna M.,
J M Day,
J. M Day,
J.M. Day,
JM Day,
Joanna Day,
Joanna M Day,
Joanna M. DAY,
Joanna M. Day
show all 10
Observed institutions:
Wellcome Centre for Cell-Matrix Research,
Hammersmith Hospital,
University of Manchester,
St Mary's Hospital,
Imperial College London,
University of Bath,
University of Birmingham
show all 7
OpenAlex ID:
A5017572010
Alternative Splicing in the Aggrecan G3 Domain Influences Binding Interactions with Tenascin-C and Other Extracellular Matrix Proteins
2004
·
Joanna M. Day
, Anders I. Olin
, et al.
·
Journal of Biological Chemistry
·
131
Design and validation of specific inhibitors of 17 -hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis
2008
·
J. M Day
, H. J Tutill
, et al.
·
Endocrine Related Cancer
·
124
PDF
17β‐hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone‐dependent breast cancer
2008
·
Joanna M. Day
, Paul A. Foster
, et al.
·
International Journal of Cancer
·
108
Kinetic resolution of the reaction catalysed by proton‐translocating transhydrogenase from Escherichia coli as revealed by experiments with analogues of the nucleotide substrates
1994
·
Mike HUTTON
, Joanna M. DAY
, et al.
·
European Journal of Biochemistry
·
88
PDF
Modification of Estrone at the 6, 16, and 17 Positions: Novel Potent Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1
2006
·
Gillian M. Allan
, Harshani R. Lawrence
, et al.
·
Journal of Medicinal Chemistry
·
76
Overexpression of 17β-Hydroxysteroid Dehydrogenase Type 1 Increases the Exposure of Endometrial Cancer to 17β-Estradiol
2012
·
Karlijn M. C. Cornel
, Roy F. P. M. Kruitwagen
, et al.
·
The Journal of Clinical Endocrinology & Metabolism
·
64
PDF
The Role of 17β-Hydroxysteroid Dehydrogenases in Modulating the Activity of 2-Methoxyestradiol in Breast Cancer Cells
2006
·
Simon P. Newman
, Christopher R. Ireson
, et al.
·
Cancer Research
·
60
STX140 Is Efficacious In vitro and In vivo in Taxane-Resistant Breast Carcinoma Cells
2008
·
Simon P. Newman
, Paul A. Foster
, et al.
·
Clinical Cancer Research
·
47
Novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1: Templates for design
2008
·
Gillian M. Allan
, Nigel Vicker
, et al.
·
Bioorganic & Medicinal Chemistry
·
40
The Development of Steroid Sulfatase Inhibitors for Hormone‐Dependent Cancer Therapy
2009
·
Joanna M. Day
, Atul Purohit
, et al.
·
Annals of the New York Academy of Sciences
·
39
Focused Libraries of 16‐Substituted Estrone Derivatives and Modified E‐Ring Steroids: Inhibitors of 17ß‐Hydroxysteroid Dehydrogenase Type 1
2006
·
Nigel Vicker
, Harshani R. Lawrence
, et al.
·
ChemMedChem
·
39
17β-Hydroxysteroid dehydrogenase Type 1 and Type 2: Association between mRNA expression and activity in cell lines
2006
·
Joanna M. Day
, Helena J. Tutill
, et al.
·
Molecular and Cellular Endocrinology
·
35
The effects of 2-substituted oestrogen sulphamates on the growth of prostate and ovarian cancer cells
2003
·
Joanna M. Day
, Simon P. Newman
, et al.
·
The Journal of Steroid Biochemistry and Molecular Biology
·
33
The regulation and inhibition of 17β-hydroxysteroid dehydrogenase in breast cancer
2006
·
A. Purohit
, H.J. Tutill
, et al.
·
Molecular and Cellular Endocrinology
·
31
The design of novel 17β-hydroxysteroid dehydrogenase type 3 inhibitors
2008
·
Nigel Vicker
, Christopher M. Sharland
, et al.
·
Molecular and Cellular Endocrinology
·
30
The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers
2007
·
S P Newman
, P A Foster
, et al.
·
British Journal of Cancer
·
26
PDF
STX140, but Not Paclitaxel, Inhibits Mammary Tumour Initiation and Progression in C3(1)/SV40 T/t-Antigen Transgenic Mice
2013
·
Florence Meyer-Losic
, Simon P. Newman
, et al.
·
PLoS ONE
·
23
PDF
BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure
2009
·
J M Day
, P A Foster
, et al.
·
British Journal of Cancer
·
21
PDF
STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model
2012
·
Joanna M Day
, Paul A Foster
, et al.
·
Endocrine Related Cancer
·
19
PDF
Order within disorder: Aggrecan chondroitin sulphate‐attachment region provides new structural insights into protein sequences classified as disordered
2010
·
Thomas A. Jowitt
, Alan D. Murdoch
, et al.
·
Proteins Structure Function and Bioinformatics
·
16
PDF
Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17β-hydroxysteroid dehydrogenase Type 3
2008
·
Joanna M. Day
, Helena J. Tutill
, et al.
·
Molecular and Cellular Endocrinology
·
16
The Folded Protein Modules of the C-terminal G3 Domain of Aggrecan Can Each Facilitate the Translocation and Secretion of the Extended Chondroitin Sulfate Attachment Sequence
1999
·
Joanna M. Day
, Alan D. Murdoch
, et al.
·
Journal of Biological Chemistry
·
16
PDF
In vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer
2014
·
C Stengel
, S P Newman
, et al.
·
British Journal of Cancer
·
14
PDF
The nature of inhibition of steroid sulphatase activity by tibolone and its metabolites
2005
·
B. Raobaikady
, J.M. Day
, et al.
·
The Journal of Steroid Biochemistry and Molecular Biology
·
12
17ß-hydroxysteroid dehydrogenase inhibitors.
2010
·
J M Day
, H J Tutill
, et al.
·
PubMed
·
9
Show more works
View as search
Works count:
44
Citation count:
1,132
H-index:
19
I10-index:
24
Year
Topic
Type
